CytoDyn (CYDY) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
12 Jan, 2026Opening remarks and agenda
Meeting called to order at 9:31 A.M. Pacific Time on November 22, 2024, as a virtual webcast.
Chair presided, with the Chief Legal Officer acting as Secretary and recording minutes.
Attendees included board members, executive team, transfer agent, and independent auditors.
Meeting conducted in accordance with company bylaws and Delaware law.
Notice of meeting and proxy materials were mailed to stakeholders of record as of September 30, 2024.
Board and executive committee updates
Five director nominees were presented for election to serve a one-year term until the 2025 annual meeting.
Nominating and Corporate Governance Committee recommended the slate of nominees.
Shareholder proposals
Three items were up for vote: election of directors, ratification of the independent accounting firm, and approval of executive compensation.
Board unanimously recommended approval of all proposals.
Latest events from CytoDyn
- Net loss of $22.6 million and legal settlement accrual raise going concern risks.CYDY
Q2 20269 Jan 2026 - Up to 120M shares may be sold for $30M to fund oncology trials, with notable dilution risk.CYDY
Registration Filing16 Dec 2025 - Biotech aims to raise $100M for oncology drug development, facing high financial and regulatory risk.CYDY
Registration Filing16 Dec 2025 - Annual meeting to vote on directors, auditor, and executive pay, with strong governance oversight.CYDY
Proxy Filing2 Dec 2025 - Shareholders will vote on director elections, auditor ratification, executive pay, and a share increase.CYDY
Proxy Filing2 Dec 2025 - Board seeks approval for director elections, auditor ratification, and share increase.CYDY
Proxy Filing2 Dec 2025 - Leronlimab advances in oncology with strong clinical data, new trials, and regulatory progress.CYDY
Proxy Filing2 Dec 2025 - Clinical-stage biotech with losses registers shares for resale; future depends on funding and leronlimab approval.CYDY
Registration Filing29 Nov 2025 - $30M equity purchase agreement provides flexible funding and safeguards shareholder interests.CYDY
Proxy Filing3 Nov 2025